glp1ledger

GLP-1 Drugs and Menopause: The Word Does Not Appear in Any of the Four Labels

There is no approved indication, and the registered research is smaller than it first looks. Fifteen studies, 963 participants — and the industry-funded ones enrol postmenopausal women to answer questions that have nothing to do with menopause.

Ronald R · Edited by Caroline S · Published 2026-09-13

Illustration: A stack of three plain notebooks and a pen on a wooden desk.
Illustration

Menopause and the drugs in this class overlap for an obvious reason: weight distribution changes around the transition, and the drugs act on weight. That overlap has produced a great deal of writing and very little evidence, and the gap between the two is unusually easy to measure.

We measured it two ways — by searching the approved labels, and by counting the registered research. Both came back smaller than expected.

Labels read 13 September 2026 from DailyMed, the National Library of Medicine's index of current FDA labelling; the trial count was taken from ClinicalTrials.gov the same day. Nothing here is medical advice, and nothing here is a dose or a schedule; our editorial standards explain why.

The word is not in any label

We searched the full current labelling of all four leading products — Ozempic, Wegovy, Mounjaro and Zepbound — for "menopause" and every variant of it.

Zero occurrences, in all four documents.

Not in the indications. Not in the warnings and precautions. Not in section 8, which is where labels address use in specific populations including pregnancy, lactation, paediatric and geriatric use. Not in the clinical studies sections describing who was enrolled.

The absence is worth pausing on, because labels are not silent about populations in general. All four have a good deal to say about pregnancy and lactation, and about patients with kidney impairment, and about paediatric and older patients. A population defined by a hormonal transition affecting roughly half of all adults at a predictable stage of life is simply not a category these documents use.

That has a practical consequence. When a reader asks what the label says about menopause, the accurate answer is not "it says to be cautious" or "it says there is no concern". It is that the question is not addressed, and an absence is not a reassurance.

The registered research, counted

A ClinicalTrials.gov query for studies combining menopause or postmenopausal status with semaglutide, tirzepatide, liraglutide or GLP-1 interventions returned 15 registered studies with a combined planned enrolment of 963 participants.

For scale: that is every registered study in this intersection, added together, against the 1,961 participants of STEP 1 or the 2,539 of SURMOUNT-1 — single trials in the same drug class.

And the 15 shrinks on inspection.

Two are not studies of these drugs at all. Both test a topical cosmetic serum in postmenopausal patients and were captured by the search because of the population rather than the intervention. A third dates from 2008 and tested an inhaled GLP-1 formulation that never reached the market, in 20 people.

Ten of the 15 have non-industry lead sponsors — universities and academic medical centres. Five are industry-led.

Where the industry money actually goes

Four of the five industry studies are Novo Nordisk's. None of them asks whether these drugs do anything for menopause.

Study Participants What it actually measures
NCT01508858 21 Whether liraglutide changes the blood levels of an oral contraceptive drug
NCT02845219 25 Whether oral semaglutide changes the pharmacokinetics of ethinylestradiol
NCT05153564 27 Blood levels of a bone marker with semaglutide and a co-administered compound
NCT07010432 144 An amylin analogue and bone metabolism

Postmenopausal women appear in the first two because their hormone levels are stable, which removes a confounder from a pharmacokinetic measurement. They appear in the latter two because postmenopausal bone loss is the reason to study bone in that group. In all four, the population is an instrument.

This is the finding, and it is not a criticism of the studies. Each is a legitimate piece of work. But anyone reading "there are industry-sponsored trials in postmenopausal women taking these drugs" as evidence that the manufacturers are investigating menopause has drawn a conclusion the registrations do not support. The industry interest in this population is real and it is aimed at contraceptive interactions and bone chemistry.

It is also worth noting which question the manufacturers have not asked. The two interaction studies examine oral contraceptives. The interaction most relevant to women at this stage of life is with menopausal hormone therapy — and that is being examined in a 96-participant academic study, NCT06715514, looking at hormone therapy alongside GLP-1 agonists and their effects on glucose and energy regulation.

The single study on the actual question

One registered study anywhere tests one of these drugs against menopausal symptoms as its subject:

NCT07218445 — "The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal" women. Sponsor: the Mayo Clinic. Planned enrolment: 40. Status on 13 September 2026: recruiting.

Vasomotor symptoms are hot flushes and night sweats. Until that study reports, statements about whether these drugs help with them — in either direction — are not resting on trial evidence, because there is no trial evidence yet to rest on.

Two larger academic studies sit adjacent to the question rather than on it: a 200-participant University of Colorado study on the menopausal transition and mid-life women's health, and a 200-participant Ohio State study combining food, fitness and medication. Neither is designed to isolate what these drugs do to menopause.

What an absence of evidence is, and is not

The 09-11 analysis on this site of GLP-1 drugs and PCOS found 31 registered trials and 3,631 participants, with every lead sponsor classified as non-industry. That absence had a clear shape: an active academic field with no commercial interest behind it.

Menopause has the opposite shape at the same low level of total evidence: fewer studies, a third of the participants, and industry sponsors who are present but asking their own questions. Both are absences; they are not the same absence, and the difference tells you something about why each gap exists.

What neither is, is evidence of harm or of futility. A question that has not been studied has not been answered either way. The honest position is that the mechanism makes the question reasonable, one 40-person trial is running, and everything else currently offered on the subject is extrapolation from trials that did not record menopausal status.

What this page does not answer

It does not say whether anyone should take one of these drugs during or after the menopausal transition, and it contains no dose and no schedule. It also cannot say how the drugs perform in this population relative to others, because the published labelling does not report results split by menopausal status — the subgroup analyses in the labels are by sex, age, race, ethnicity and region, and menopausal status is not among them.

Related reading: the population question with a fuller evidence base is PCOS; the bone and body-composition question sits alongside muscle loss; and what happens when treatment stops is on stopping a GLP-1.

Sources

A registry count is a measure of what has been registered, not of everything being studied, and studies are added continually. The count above is dated and the query is described so that it can be repeated.

Frequently asked questions

Are GLP-1 drugs approved for menopause symptoms?

No. None of them holds any menopause-related indication, and the word does not appear anywhere on the current Ozempic, Wegovy, Mounjaro or Zepbound labels — not in the indications, not in the warnings, not in the sections describing use in specific populations. Anyone prescribed one of these drugs around menopause is being prescribed it for an approved use such as weight management, type 2 diabetes or cardiovascular risk reduction, or off-label. Labels read 13 September 2026.

Is there research on GLP-1 drugs and menopause?

Very little, and less than the headline count suggests. A ClinicalTrials.gov search on 13 September 2026 returned 15 registered studies with 963 planned participants in total — fewer people than a single pivotal obesity trial. Two are not studies of these drugs at all. Of the rest, most either enrol postmenopausal women to answer an unrelated question or examine bone outcomes. One study anywhere tests one of these drugs against menopausal symptoms as its subject.

Do these drugs help with hot flushes?

Nobody knows, and the study designed to find out is still recruiting. NCT07218445 at the Mayo Clinic is testing tirzepatide against menopausal vasomotor symptoms — the clinical term for hot flushes and night sweats — with a planned enrolment of 40. Until it reports, any claim in either direction is not resting on trial evidence.

Why do so many of the registered trials enrol postmenopausal women if they are not about menopause?

Because stable hormone levels make that population methodologically convenient. Two of the Novo Nordisk studies in the search are drug-interaction trials measuring whether these drugs change the blood levels of oral contraceptive hormones; postmenopausal participants are used so that endogenous cycling does not confound the measurement. Others examine bone markers, where postmenopausal bone loss is the reason to study that group. The population is a tool in these studies, not the subject.

Is it safe to take a GLP-1 drug alongside menopausal hormone therapy?

The labels do not address the combination and the question is under study rather than answered. A 96-participant academic study (NCT06715514) is examining menopausal hormone therapy alongside GLP-1 agonists and their effects on glucose and energy regulation. Notably, the manufacturers' own interaction studies in this area looked at oral contraceptives rather than menopausal hormone therapy. Whether any individual combination is appropriate is a question for a prescriber.

Do these drugs work differently after menopause?

The published labelling does not report results split by menopausal status. The pivotal weight-management trials enrolled large numbers of women across the age range at which the transition occurs, and the labels report subgroup analyses by sex and by age but not by menopausal status. The information may exist in trial datasets; it is not in the documents a reader can check.

Should menopause change how someone thinks about these drugs?

That is a decision question, and this site answers information questions rather than decision questions. What can be stated is the state of the evidence: no approved indication, no mention in any label, and a registered research base of fewer than a thousand planned participants, most of it aimed at something other than menopause itself.

Is the research on menopause worse than on other off-label uses?

It is differently bad, and the comparison is instructive. When we counted registered trials for polycystic ovary syndrome we found 31 studies and 3,631 participants — a larger field, but with every lead sponsor classified as non-industry. Menopause has fewer studies and fewer participants, and does have industry sponsors, but those sponsors are asking questions of their own that happen to use this population. In PCOS the money is absent; here it is present and pointed elsewhere.